Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma

Archives of Neurology

Volumn 65, Issue 10, 2008, Pages 1378-1379

  Madray, Monica M ^a   Greene Jr , John F ^a   Butler, David F ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD30 ANTIGEN; DESOGESTREL PLUS ETHINYLESTRADIOL; GLATIRAMER; PAROXETINE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOID CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REMISSION; STAINING;

ADULT; ANTIGENS, CD30; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LEG; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEOPLASM, RESIDUAL; PEPTIDES; RADIOTHERAPY; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 54049098341     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.10.1378     Document Type: Article

References (6)

1. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics. 2007;4(4):647-653.
2. Bosca I, Bosca M, Belenguer A, et al. Necrotising cutaneous lesions as a side effect of glatiramer acetate. J Neurol. 2006;253(10):1370-1371.
3. Thouvenot E, Hillaire-Buys D, Bos-Thompson MA, et al. Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis. Mult Scler. 2007;13(7):941-944.
4. Nolden S, Casper C, Kuhn A, Petereit HF. Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate. Mult Scler. 2005;11(2):245-248.
5. Droc C, Cualing HD, Kadin ME. Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin. Cancer Control. 2007;14(2):124-132.
6. Di Lernia V, Viglio A, Cattania M, Emilia R, Paulli M. Carbamazepine-induced, CD30+, primary, cutaneous, anaplastic large-cell lymphoma. Arch Dermatol. 2001;137(5):675-678.